Quantitative structure-activity relationship study of novel alpha1a-selective adrenoceptor antagonists.
Two series of compounds were recently reported as novel alpha1a-selective adrenoceptor antagonists. In the first series, a dihydropyrimidone moiety is attached to a 4-phenyl piperidine containing side chain, while in the second, it is linked to a 4-substituted phenyl piperazine containing side chain. These compounds having potential for the treatment of benign prostatic hyperplasia, a urological disorder in the older age male population, were subjected to a quantitative structure-activity relationship study. The analysis has helped to ascertain the role of different substituents in explaining the observed binding potencies of these analogues. In the first category of compounds, three sites R1, R2, and X were varied and from the quantitative structure-activity relationship, it emerged that X- and R1-substituents having respectively, the high values of field and resonance effects may lead to more potent alpha1a-antagonists. The substituent of R2, being either CH3 or C2H5, does not add to improve the activity and thus the site, at present, becomes redundant. This site may, however, be explored for some additional substituents in future. In the second series of compounds, the phenyl ring, linked to a piperazine moiety at the end of a side chain, was substituted with various groups onto different positions. From derived significant correlations, it appeared the less polar and/or bulky substituents at the meta- and para-positions and a more hydrophobic substituent at the para-position are advantageous.
Singh
P
P
Department of Chemistry, S.K. Government College, Sikar, India.
Kumar
R
R
D000322:Adrenergic Agonists / Q000737:chemistry* / Q000494:pharmacology; D058668:Adrenergic alpha-1 Receptor Antagonists; D001665:Binding Sites; D006801:Humans; D008297:Male; D010879:Piperazines / Q000737:chemistry / Q000494:pharmacology; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology; D011470:Prostatic Hyperplasia / Q000188:drug therapy; D011744:Pyrimidinones / Q000737:chemistry / Q000494:pharmacology; D021281:Quantitative Structure-Activity Relationship
D000322:Adrenergic Agonists; D058668:Adrenergic alpha-1 Receptor Antagonists; D010879:Piperazines; D010880:Piperidines; D011744:Pyrimidinones; C048151:4-phenylpiperidine; C031503:phenylpiperazine